People living with T1D are at higher risk for long-term complications affecting the heart and cardiovascular system, eyes, kidneys and peripheral nerves. Ongoing T1D research recognizes the need for more options for treating or preventing these complications within the T1D population. Rainier Clinical Research Center in Seattle is currently recruiting for two such studies:

Merck Cholesterol Study:

This study is evaluating the efficacy and safety of an investigational drug MK-0616, compared with ezetimibe, bempedoic acid, or the combination of ezetimibe + bempedoic acid in adults with high cholesterol. MK-0616 reduces cholesterol by increasing the clearance of cholesterol particles (specifically LDL particles) from the blood. MK-0616 is an oral version of PSCK9 inhibitor injectables. Injectable PSCK9 inhibitors are already FDA-approved for the treatment of high cholesterol in people with known cardiovascular disease or with a genetic form of hypercholesterolemia.

Rainier Clinical Research Center is looking for volunteers with high cholesterol, who also have cardiovascular disease or are at high risk for cardiovascular disease. Adults with high cholesterol and type 1 diabetes are at higher risk of cardiovascular disease and potentially would qualify. Participants must also be taking a statin medication.

This study will last 5 months with 5 in-person visits. Compensation is $650 for study completion.

LXBD/ Diabetic Peripheral Neuropathy:

This study will be evaluating the efficacy of investigational drug LY3556050 compared to placebo in reducing the pain associated with diabetic peripheral neuropathy. LY3556050 is a novel drug that reduces pain by interrupting the transmission of pain signals along sensory nerves to the brain. LY3556050 is an oral medication.

Rainier Clinical Research Center is looking for individuals with type 1 or type 2 diabetes who have been diagnosed with diabetic peripheral neuropathy for at least 6 months.

This study will last up to 24 weeks and includes 9 in-person visits. Participants will be compensated up to $1,830 for study completion.

If you are interested in these studies, please contact Rainier Clinical Research Center at recruitment@rainier-research.com.